Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0030567 (
Parkinson's disease
)
63,064
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Levels of
DARP
in the cerebrospinal fluid (CSF) of patients having a wide variety of neurological disorders were determined. Neurological disorders were categorized as degenerative, demyelinating, epilepsy, trauma, hydrocephalia, inflammatory, A-V malformation, CNS neoplasia, parasitic and stroke.
DARP
levels were determined by an enzyme-linked immunoabsorbent assay (ELISA) using monoclonal anti-
DARP
antibodies. A synthetic peptide corresponding to the first 36 aa of the N-terminal of
DARP
was used as standard. A total of 7 non-neurological patients and 73 patients with neurological disorders were tested. The relative concentrations of
DARP
decreased in patients with Parkinson's diseases vs. patients with non-neurological diseases and increased in other neuropathologies such as demyelinating, hydrocephalia and A-V malformations. Data obtained suggest that changes in the percentage and concentration of
DARP
may correlate with certain neurological disorders, showing particularly low levels in
Parkinson's disease
patients.
...
PMID:Determination of dopamine-releasing protein (DARP) in cerebrospinal fluid of patients with neurological disorders. 942 87
